Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 2:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1.3% Liposomal Bupivacaine Clear all
Suspended Phase 4 Interventional

Liposomal Bupivacaine in One-level Instrumented Posterior Spinal Fusion

NCT03745040
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Lumbar Disc Herniation, Lumbar Disc Disease, Lumbar Spondylolisthesis
Interventions
Liposomal bupivacaine
Drug
Lead sponsor
Allina Health System
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 1, 2026, 2:07 PM EDT
Not listed Phase 4 Interventional

Liposomal Bupivacaine Intercostal Nerve Block vs Thoracic Epidural for Regional Analgesia in Multiple Rib Fractures

NCT03574376
View directory record Official record
Conditions
Trauma, Trauma Injury, Pain, Acute
Interventions
Bupivacaine Liposome Injection, Bupivacaine
Drug
Lead sponsor
Chadrick Evans
Other
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Exparel Versus Bupivacaine in Post-operative Pain Control

NCT06547255
View directory record Official record
Conditions
Liposomal Bupivacaine
Interventions
Bupivacaine liposome injectable suspension
Drug
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Liposomal Bupivacaine Versus Interscalene Nerve Block

NCT03929146
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Exparel, Interscalene Nerve Block
Drug · Procedure
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Phase 3 Interventional

Liposomal Bupivacaine To Control Post-Operative Pain Following BMG

NCT03720223
View directory record Official record
Conditions
Urethral Stricture
Interventions
Liposomal Bupivacaine
Drug
Lead sponsor
Urology of Virginia
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Virginia Beach, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 1, 2026, 2:07 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant

NCT03737604
View directory record Official record
Conditions
Transplant;Failure,Kidney, Pain, Postoperative
Interventions
Ropivacaine Continuous Infusion Catheter, Single Dose Liposomal Bupivicaine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 1, 2026, 2:07 PM EDT
Recruiting Phase 4 Interventional

EXPAREL Post-tonsillectomy Clinical Trial

NCT03420638
View directory record Official record
Conditions
Tonsillectomy
Interventions
Adjunct Exparel (bupivacaine liposome suspension 1.3%), Standard Care
Drug · Other
Lead sponsor
Paul Hoff
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Ann Arbor, Michigan • Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 1, 2026, 2:07 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

ESP vs QL for Total Abdominal Hysterectomy

NCT04074226
View directory record Official record
Conditions
Postoperative Pain
Interventions
Erector Spinae Plane block, Quadratus Lumborum Block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 1, 2026, 2:07 PM EDT
Recruiting Phase 4 Interventional

Post Operative Infusion Pump Pain Study

NCT07349810
View directory record Official record
Conditions
Post Operative Pain
Interventions
Bupivacaine 0.5% Injectable Solution, Ropivacaine 0.2% Injectable Solution, 1.3% liposomal bupivacaine (Exparel), ambIT Infusion Pump
Drug · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Somerset, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 1, 2026, 2:07 PM EDT
Terminated Phase 4 Interventional

Liposomal Bupivacaine Infiltration vs Continuous Perineural Ropivacaine Infusion for Post-operative Pain After Total Shoulder Arthroplasty

NCT02787226
View directory record Official record
Conditions
Postoperative Pain, Shoulder Arthritis
Interventions
Liposomal Bupivacaine Infiltration, Continuous Perineural Ropivicaine Infusion
Drug
Lead sponsor
Eric Shepard
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2018 · Synced Oct 1, 2026, 2:07 PM EDT
Recruiting Phase 4 Interventional

Liposomal Bupivacaine/Bupivacaine in Rectus Sheath Blocks Versus Ropivacaine in Rectus Sheath Blocks And Catheters

NCT05972018
View directory record Official record
Conditions
Aortic Aneurysm, Abdominal, Abdominal Aortic Occlusion, Aortoiliac Occlusive Disease, Aortic Diseases
Interventions
Liposomal bupivacaine, Ropivacaine, Bupivacain
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety, of EXPAREL Administered as Sciatic Nerve Block (In Popliteal Fossa), for Postsurgical Analgesia in Subjects Undergoing Bunionectomy

NCT04002089
View directory record Official record
Conditions
Bunion
Interventions
Exparel Injectable Product, Bupivacaine
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pain Control in Colorectal Surgery: Liposomal Bupivacaine Block Versus Intravenous Lidociane

NCT04005859
View directory record Official record
Conditions
Colorectal Disorders
Interventions
Exparel, IV Lidocaine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 1, 2026, 2:07 PM EDT
Not listed Not applicable Interventional

Effect of Local Anesthesia on Postoperative Pain Following Sacrospinous Ligament Fixation

NCT02890199
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Bupivacaine liposomal, Lidocaine
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 95 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 12, 2016 · Synced Oct 1, 2026, 2:07 PM EDT
Terminated Phase 4 Interventional Results available

The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics

NCT03290196
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
EXPAREL 1.3 % in 20 ML Injection
Drug
Lead sponsor
Andrews Research & Education Foundation
Other
Eligibility
18 Years to 72 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Gulf Breeze, Florida
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL Administered as a Pectoral Plane Block in Women Undergoing Breast Augmentation

NCT04293809
View directory record Official record
Conditions
Breast Augmentation
Interventions
Exparel Injectable Product, Bupivacaine Hydrochloride
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 1, 2026, 2:07 PM EDT
Withdrawn Phase 3 Interventional

Liposomal Bupivacaine in Shoulder Arthroscopy

NCT04461028
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Liposomal bupivacaine, Bupivacaine with Dexamethasone Solution
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Phase 4 Interventional Results available

Exparel for Postoperative Pain Management in Shoulder Surgery

NCT02472314
View directory record Official record
Conditions
Fracture of Shoulder and Upper Arm
Interventions
1.3% Liposomal Bupivacaine, 0.125% Bupivacaine
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 29, 2023 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Liposomal Bupivacaine Plus Bupivacaine Peripheral Nerve Blockade Versus Ropivacaine Plus Dexamethasone Peripheral Nerve Blockade for Arthroscopic Rotator Cuff Repair

NCT04737980
View directory record Official record
Conditions
Rotator Cuff Tears, Shoulder Pain
Interventions
Liposomal bupivacaine, Bupivacaine Hcl 0.5% Inj, Ropivacaine 0.5% Injectable Solution, Dexamethasone
Drug
Lead sponsor
Hospital for Special Surgery Florida
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 8, 2021 · Synced Oct 1, 2026, 2:07 PM EDT
Terminated Phase 3 Interventional Results available

0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka

NCT03303794
View directory record Official record
Conditions
Anesthesia
Interventions
Exparel, 0.25% bupivacaine
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Phase 4 Interventional Results available

PAIN - Postoperative Analgesia INvestigation

NCT02111746
View directory record Official record
Conditions
Postoperative Pain
Interventions
Exparel, Bupivacaine hydrochloride, Patient Controlled Analgesia (PCA)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Not applicable Interventional

Interscalene Catheter vs. Interscalene Liposomal Bupivacaine for Arthroscopic Rotator Cuff Repair

NCT04571606
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Single injection peripheral nerve block with liposomal bupivacaine (Exparel), Single injection peripheral nerve block with 0.25% bupivacaine and subsequent peripheral nerve catheter with 0.2% bupivacaine infusion via onQ pain pump
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 1, 2026, 2:07 PM EDT
Recruiting Phase 4 Interventional

Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

NCT05224089
View directory record Official record
Conditions
Bowel Disease
Interventions
Liposomal Bupivicaine/Bupivacaine Admixture, Bupivacaine HCL
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 1, 2026, 2:07 PM EDT
Completed Phase 4 Interventional Results available

Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction

NCT02189317
View directory record Official record
Conditions
Anterior Cruciate Ligament Rupture
Interventions
Exparel
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 1, 2026, 2:07 PM EDT